Acute Lung Injury, Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS), Acute Respiratory Distress Syndrome, Traumatic Brain Injury
Conditions
Keywords
Non-invasive Vagal Nerve Stimulation
Brief summary
This is a prospective, randomized, two-arm, controlled 30-day investigational pilot trial using the gammaCore Sapphire S non-invasive vagus nerve stimulation (nVNS) device + standard of care (SOC) in newly-hospitalized patients with mild-to-moderate traumatic brain injury (TBI) to prevent the progression towards immunokine storms, systemic inflammatory response syndrome (SIRS), severe respiratory distress, and requirement for invasive mechanical ventilation, and death, when compared to SOC alone (the control arm).
Detailed description
A pilot population of 46 individuals between 18-80 years of age inclusive, will be enrolled, with an in-trial monitoring period of up to 30 days following baseline measurements. Study subjects will remain in-trial until one of the following occurs: a) 30 days without any progression to respiratory distress requiring mechanical ventilation; b) requirement for mechanical ventilation prior to 30 days; or c) death prior to 30 days. In addition to the screening, a total of up to 5 additional in-trial events (depending on the time at discharge from hospitalization) plus one additional clinical site visit at the end of the follow-up period will comprise the study events schedule of this trial.
Interventions
DEVICEnVNS
3x daily treatment of nVNS + SOC
OTHERSOC
Standard of care patient management.
Sponsors
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
ElectroCore INC
Chuck Noll Foundation
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
12 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. Patient is between 12-80 years, inclusive 2. Patient has been admitted to the hospital for mild-to-moderate TBI that is restricted to the head and/or neck region. 3. Patient is not on invasive mechanical ventilation 4. Patient has a mild-to-moderate TBI based on a non-resuscitated or post-resuscitated Glasgow Coma Scale (GCS) sum score of =\>12 5. Patient has a Lung Injury Prediction Score (LIPS) of =\>2 6. Administration of the first nVNS treatment must be planned to take place within 24 h of intake 7. A signed, written informed consent form from the patient or legally authorized representative
Exclusion criteria
1. Patient has a diagnosis of moderate or greater grade of respiratory distress/ARDS according to the Berlin definition of ARDS: Partial pressure of oxygen (PaO2) /Fraction of Inspired Oxygen (FiO2) \> 100 mmHg (\>13.3 kPa) to ≤ 200 mmHg (≤ 26.6 kPa) with positive end-expiratory pressure (PEEP) ≥ 5 cmH2O) 2. Woman known to be pregnant, lactating or with a positive (urine or serum test) or indeterminate (serum test) pregnancy test 3. Patient simultaneously taking part in another clinical trial 4. Patient is not expected to survive for 24 hours 5. Patient has an underlying clinical condition where, in the opinion of the study physicians and the institutional health provider physician, it would be extremely unlikely that the patient would not progress to invasive mechanical ventilation within 48 hours or any other condition that might require immediate invasive mechanical ventilation (e.g. motor neuron disease, Duchenne muscular dystrophy, or rapidly-progressive interstitial pulmonary fibrosis) 6. Patient has severe chronic obstructive pulmonary disease (COPD) requiring long-term home oxygen therapy or mechanical ventilation (non-invasive ventilation or via tracheotomy) except for continuous positive airway pressure (CPAP) or bi-level positive airway pressure (BIPAP) used solely for sleep-disorder breathing 7. Patient has congestive heart failure 8. Patient has acute left ventricular failure 9. Patient has liver failure (Child-Pugh grade C) 10. Patient is receiving renal dialysis therapy for chronic renal failure 11. Patient is receiving extracorporeal membrane oxygenation, high-frequency oscillatory ventilation (HFOV) or any form of extracorporeal lung support 12. Patient has had any form of mechanical ventilation (invasive or non-invasive, excluding CPAP alone) for longer than 48 h prior to the diagnosis of mild-to-moderate respiratory distress/ARDS 13. Patient has burns to ≥ 15% of their total body surface area
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| All-Cause 90-Day Admission to Any Hospital or ED Encounter | 90 days | A composite endpoint of 90-day presentation to any emergency department and/or 90-day admission to any hospital. |
Secondary
| Measure | Time frame |
|---|---|
| Number of Participants With AEs/SAEs Up to 30 Days From Baseline | 30 days from baseline |
| Number of Participants With Abnormal Physical Examination by Day 30 | 30 days from baseline |
| Number of Participants With Abnormal Vital Signs by Day 30 | 30 days from baseline |
| Number of Participants With Abnormal Laboratory Results by Day 30 | 30 days from baseline |
Countries
United States
Contacts
STUDY_DIRECTORSarah Kimutis
Allegheny Health Network
Baseline characteristics
| Characteristic | — |
|---|---|
| Age, Continuous | 29 years |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 3 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 3 Participants |
| Sex: Female, Male Female | 1 Participants |
| Sex: Female, Male Male | 1 Participants |
| Smoking Status Non-smoker | 2 Participants |
| Smoking Status Smoker | 0 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 1 | 0 / 2 |
| other Total, other adverse events | 0 / 1 | 0 / 2 |
| serious Total, serious adverse events | 0 / 1 | 0 / 2 |
Outcome results
None listed